XOMA News and Press, XOMA Corporation From 01/18/24

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases XOMA is entitled to no less than 50% of the potent...

2024-01-12 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-12 07:44:58 ET More on LadRx, XOMA, etc. XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA Fina...

EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA) acceptance of Zevra Therapeutics’ New Drug Application (NDA) for arimoclomol, an orall...

2024-01-08 08:16:18 ET More on XOMA XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA Seeking Alpha’s Quant Rating on XOMA Historical earnings data for XOMA ...

EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA...

2024-01-02 10:18:19 ET More on XOMA XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA Seeking Alpha’s Quant Rating on XOMA Historical earnings data for XOMA ...

EMERYVILLE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized XOMA’s first stock repurchase program, which permits the Company to purchase up to $50 million of XOMA’s commo...

2023-12-30 00:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-29 07:00:00 ET Summary XOMA Corporation specializes in financing new drug development and offers preferred stocks as investment options. XOMA's strategy involves acquiring economic rights to future milestones and royalty payments associated with partnered pre-commercial cl...